Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

BMY teams with BioNTech on BNT327, a dual-target cancer therapy, as legacy drugs face mounting generic pressure ...

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

Healthcare companies are navigating a challenging environment as policy uncertainty and competitive pressures weigh on the ...

The Trump administration is eroding national pandemic flu defenses as it guts health agencies, cuts research and health ...

US drug companies are increasingly licensing experimental medicines invented by Chinese firms. The recent deals could be ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

With U.S. stocks booming, North American wealthy led the way globally. And the top 1% of wealthy globally—the so-called ...

India has reported a sudden rise in COVID cases, starting from late May. Authorities said the number of active cases of the ...

The fraught discussions playing out between President Donald Trump and one of the world’s most powerful figures could shape ...

Experts say Robert F. Kennedy Jr. has talked about "freedom of choice" in health care while limiting choices on some products ...

QuantumScape has logged a -27.6% 52 week change, compared to 11.1% for the S&P 500 QS has an average analyst rating of hold ...